Merck & Co. Overview

  • Year Founded
  • 1891

Year Founded

  • Status
  • Public

  • Employees
  • 75,000

Employees

  • Stock Symbol
  • MRK

Stock Symbol

  • Investments
  • 106

  • Share Price
  • $78.28
  • (As of Tuesday Closing)

Merck & Co. General Information

Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Contact Information

Website
www.merck.com
Formerly Known As
Schering Plough
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 126 East Lincoln Avenue
  • PO Box 2000
  • Rahway, NJ 07065
  • United States
+1 (908)
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NYS
Vertical(s)
Corporate Office
  • 126 East Lincoln Avenue
  • PO Box 2000
  • Rahway, NJ 07065
  • United States
+1 (908)

Merck & Co. Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck & Co. Stock Performance

As of 17-Jun-2025, Merck & Co.’s stock price is $78.28. Its current market cap is $197B with 2.51B shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$78.28 $80.96 $73.31 - $134.63 $197B 2.51B 16.2M $6.89

Merck & Co. Financials Summary

As of 31-Mar-2025, Merck & Co. has a trailing 12-month revenue of $63.9B.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 250,218,013 275,244,154 302,399,197 300,538,183
Revenue 63,922,000 64,168,000 60,115,000 59,283,000
EBITDA 25,613,000 25,291,000 6,542,000 21,158,000
Net Income 17,434,000 17,117,000 365,000 14,519,000
Total Assets 115,122,000 117,106,000 106,675,000 109,160,000
Total Debt 34,844,000 37,111,000 35,055,000 30,691,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Merck & Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck & Co.‘s full profile, request access.

Request a free trial

Merck & Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabo
Pharmaceuticals
Rahway, NJ
75,000 As of 2024

London, United Kingdom
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Merck & Co. Competitors (42)

One of Merck & Co.’s 42 competitors is GSK, a Corporation company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GSK Corporation London, United Kingdom
Pfizer (Pharmaceuticals) Corporation New York, NY
AstraZeneca Formerly PE-Backed Cambridge, United Kingdom
Gilead Sciences Formerly VC-backed Foster City, CA
Bristol-Myers Squibb Corporation Princeton, NJ
You’re viewing 5 of 42 competitors. Get the full list »

Merck & Co. Patents

Merck & Co. Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250161420-A1 Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease Pending 16-Nov-2023
US-20250152658-A1 Cyclic peptide for trapping interleukin-1 beta Pending 14-Nov-2023
US-20250154173-A1 Ripk1 inhibitors and methods of use Pending 02-Nov-2023
US-20250136910-A1 Devices for use as blood brain barrier models Pending 25-Oct-2023
US-20250136615-A1 Small molecule inhibitors of kras proteins Pending 20-Oct-2023 C07D498/22
To view Merck & Co.’s complete patent history, request access »

Merck & Co. Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Merck & Co. Investments & Acquisitions (106)

Merck & Co.’s most recent deal was a Corporate Asset Purchase with WuXi (15,520 Square Meter Vaccine Plant in Dundalk, Ireland) for . The deal was made on 06-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
WuXi (15,520 Square Meter Vaccine Plant in Dundalk, Ireland) 06-Jan-2025 Corporate Asset Purchase Buildings and Property
WuXi Biologics (Vaccine Facility in Ireland) 06-Jan-2025 Corporate Asset Purchase Medical Supplies
LaNova Medicines (Global Rights for Cancer Bispecific Antibody LM-299) 20-Dec-2024 Corporate Asset Purchase Buildings and Property
Personalis 19-Dec-2024 PIPE Drug Discovery
Aktis Oncology 20-Sep-2024 Early Stage VC Drug Discovery
You’re viewing 5 of 106 investments and acquisitions. Get the full list »

Merck & Co. ESG

Risk Overview

Risk Rating

Updated June, 03, 2025

18.81 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view Merck & Co.’s complete esg history, request access »

Merck & Co. Exits (37)

Merck & Co.’s most recent exit was on 21-Dec-2023 from Evaxion. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Evaxion 21-Dec-2023 Completed
Kelun Biotech 29-Dec-2022 Completed
  • 9 buyers
Ponea Health 01-Sep-2022 Completed
  • 7 buyers
Syapse 28-Jul-2022 Completed
  • 7 buyers
Vence 16-Mar-2022 Later Stage VC Completed
  • 5 buyers
You’re viewing 5 of 37 exits. Get the full list »

Merck & Co. Affiliates

Subsidiaries (11)

Name Industry Location Year Founded
Caraway Therapeutics Cambridge, MA 2018
Merck Animal Health Ventures Rahway, NJ 2017
MRL Ventures Fund Cambridge, MA 2015
Peloton Therapeutics Dallas, TX 2011
Merck Global Health Innovation Fund Rahway, NJ 2010
You’re viewing 5 of 11 affiliates. Get the full list.  »

Merck & Co. FAQs

  • When was Merck & Co. founded?

    Merck & Co. was founded in 1891.

  • Where is Merck & Co. headquartered?

    Merck & Co. is headquartered in Rahway, NJ.

  • What is the size of Merck & Co.?

    Merck & Co. has 75,000 total employees.

  • What industry is Merck & Co. in?

    Merck & Co.’s primary industry is Pharmaceuticals.

  • Is Merck & Co. a private or public company?

    Merck & Co. is a Public company.

  • What is Merck & Co.’s stock symbol?

    The ticker symbol for Merck & Co. is MRK.

  • What is the current stock price of Merck & Co.?

    As of 17-Jun-2025 the stock price of Merck & Co. is $78.28.

  • What is the current market cap of Merck & Co.?

    The current market capitalization of Merck & Co. is $197B.

  • What is Merck & Co.’s current revenue?

    The trailing twelve month revenue for Merck & Co. is $63.9B.

  • Who are Merck & Co.’s competitors?

    GSK, Pfizer (Pharmaceuticals), AstraZeneca, Gilead Sciences, and Bristol-Myers Squibb are some of the 42 competitors of Merck & Co..

  • What is Merck & Co.’s annual earnings per share (EPS)?

    Merck & Co.’s EPS for 12 months was $6.89.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »